Close
FINDING CURES TOGETHER<sup>SM</sup>
  • Home
  • Funding
  • The AACR-Conquer Cancer Foundation of ASCO Young Investigator Award for Translational Cancer Research

‚ÄčThe AACR-Conquer Cancer Foundation of ASCO Young Investigator Award for Translational Cancer Research

The AACR-Conquer Cancer Foundation of ASCO Young Investigator Award for Translational Cancer Research provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this jointly-supported award is to fund a physician-scientist during the transition from a fellowship program to a faculty appointment. Research projects are restricted to translational cancer research.

2018 Grantee

Anastasios Dimou, MDAnastasios Dimou, MD
Fellow
University of Colorado
Aurora, Colorado
headshot_1 line spacerMHC genotype is shaping the risk for EGFR mutation driven lung cancer

Scientific Statement of Research
There has been a renewed interest in harnessing the immune system to improve treatment for lung and other cancers. Genomic mutations in tumors can form neoantigens and elicit immune responses; however, the interplay between the host genotype with respect to the human leukocyte antigen (HLA) alleles and cancer evolution has not been well studied. Dr. Dimou will test the hypothesis that specific host HLA alleles may decrease the incidence of particular EGFR mutations. To achieve this goal, he will update and validate an existing next generation sequencing (NGS) assay to determine the HLA genotype of tumor samples, apply this assay to a large clinical cohort of EGFR mutation positive lung cancers and determine associations between the specific EGFR mutations (e.g., L858R) and MHC class I alleles. Ultimately, he will investigate whether genetic interactions between germline variations and somatic mutations contribute to differences in tumor evolution.

Biography
Anastasios Dimou obtained his MD from the University of Athens and pursued post-doctoral studies in the laboratory of David Rimm at Yale University where he focused on biomarker development. He trained in Internal Medicine at Albert Einstein Medical Center and in Hematology-Oncology at Medical University of South Carolina where he studied the molecular pathway of neuropilins in the laboratory of Harry Drabkin and Robert Gemmill. Dr. Dimou has currently joined the laboratory of Robert Doebele at University of Colorado. His interests include the interactions of tumor mutations with the host genome and strategies to overcome tumor resistance to targeted therapies.

Acknowledgement of Support
I am extremely honored to receive the prestigious 2018 AACR-Conquer Cancer Foundation of ASCO Young Investigator Award for Translational Cancer Research. These funds will support my research on understanding the development of central tolerance to key cancer driving oncogenes.

Top of page

Search other AACR research funding opportunities.